skip content
NIH Research Festival 2006
2006 NIH Research Festival

<< Back < Home
October 17 - October 20
General Schedule of Events
Poster Sessions
Plenary Session
Concurrent Symposia
Job Fair for NIH Postdoctoral, Research, and Clinical Fellows
Special Exhibits on Resources for Intramural Research
TSA Research Festival Exhibit Show
Festival Food and Music Fair
Research Festival Committees
Past Research Festivals
Concurrent Symposia
  Wednesday, October 18, 2006
Natcher Auditorium

Human Papillomavirus (HPV) and Cervical Cancer: From Pathogenesis to Prevention

2:30 pm to 4:30 pm

Co-chaired by Douglas R. Lowy, NCI, and Philip E. Castle, NCI

Balcony C, Natcher Conference Center

This session will highlight the enormous progress that builds on the conclusion that infections by a group of carcinogenic human papillomaviruses (HPVs) cause several cancers, including virtually all cases of cervical cancer, which is the second leading cause of cancer and cancer-related mortality in women worldwide.  Carcinogenic HPV is also the etiologic agent of approximately 30% of oropharyngeal cancer, as well as being linked to cancers of the oropharynx, anus, vagina, and vulva.  The knowledge of the central role of HPV in cervical carcinogenesis, and delineation of the natural history of HPV infection, is being translated into new technologies for primary and secondary prevention.  NIH investigators are playing a leading role in these advances.  Technologies for primary prevention of HPV infection include the highly efficacious virus-like particle (VLP) vaccines against HPV16 and HPV18, the two HPV types that cause 70% of cervical cancer and account for an even higher percentage of the other cancers attributable to HPV, and the potential for the development of potent vaginal microbicides that could target the full spectrum of genital HPV infections.  For secondary prevention, HPV DNA testing has been shown to be substantially more accurate and reproducible than the Pap smear for detection of treatable precancerous and cancerous cervical lesions.  To achieve large reductions in the global incidence of cervical cancer, these technologies must now be adapted and/or made available to low-resource and underserved populations of women, as more than 80% of cervical cancer occurs in these populations.


HPV as the Necessary Cause of Cervical Cancer: Implications for Primary and Secondary Prevention
Philip E. Castle, NCI

HPV Vaccines to Prevent Cervical Cancer
John T. Schiller, NCI

Topical Microbicides Targeting HPV
Christopher B. Buck, NCI

HPV Vaccine Implementation and Cervical Cancer Screening: Combining Personal Health Information and Public Health Awareness
Carolyn Deal, NIAID

National Institutes of Health (NIH) Department of Health and Human Services USA Gov Website